A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Absci Corporation ABSI

Mixed (early) Emerging Frontier sector · Absci — generative-AI antibody drug design, early-stage and speculative.

Key quality signals

Revenue growth (YoY)—

Gross margin—

Gross profits / assets-0.12

Rule of 40-7062.7

Net margin-7000.8%

Cash runway (months)15.5

PEG—

P/S580

Risk flags

Burning cash — operating margin is negative.Heavy dilution (~23%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+24%) in the last month — extreme single-day moves tend to mean-revert.

Positive signals

Insider cluster buying — 2 insiders bought on the open market in the last 90 days (the one insider pattern with robust positive evidence).

Insider & analyst context

Insider 90-day: 2 cluster buyer(s), 0 seller(s). Insider selling is routine diversification, not a bearish signal.
Analyst mix: 4 strong-buy / 10 buy / 2 hold / 0 sell. Ratings are context, not a price target.

Similar Emerging Frontier names

Centrus Energy Corp.BigBear.ai Holdings, Inc.Kratos Defense & Security Solutions, Inc.Nano Nuclear Energy IncOuster, Inc.SoundHound AI, Inc.

← All Emerging Frontier names · Open ABSI in the interactive screener →

Data as of 2026-06-09 22:43 (end-of-day). How grades are computed →